1. Introduction
===============

Riboviruses, viruses with RNA genomes, contain the largest number of viruses with significant impact on human health. Several of these agents are associated with significant biohazard concerns and can be manipulated only under the highest biosafety level conditions (BSL4), which complicates research aimed at understanding their biology and pathogenesis, as well as the identification and characterization of antiviral drugs to combat them.

The term reverse genetics, as used in the field of molecular virology, refers to the generation or "rescue" of viruses entirely from cloned cDNAs. This approach was first implemented for the generation and genetic manipulation of positive strand RNA viruses, whose deproteinized genomes are able to act as mRNA and initiate the virus life cycle once delivered into appropriate susceptible cells. In contrast, the template of the polymerases of negative strand (NS) RNA viruses is exclusively a nucleocapsid consisting of the genomic RNA tightly encapsidated by the virus nucleoprotein (N), which associated with the virus polymerase proteins forms a ribonucleoprotein (RNP) complex. This RNP is active in transcription and replication and is the minimum unit of infectivity. Consequently, deproteinized genomes of NS RNA viruses cannot function as mRNAs and are not infectious. Thus, generation of biologically active synthetic NS viruses from cDNA will require *trans* complementation by all of the viral proteins involved in virus replication and transcription.

These considerations initially posed unique hurdles to the development of reverse genetics systems for NS RNA viruses ([@bib79], [@bib22]). However, during the last 15 years, following the pioneering work of Palese\'s group ([@bib68]), significant progress has been made in this area and reverse genetics systems have been now developed for all ribovirus families. These developments have revolutionized the analysis of *cis*-acting sequences and *trans*-acting proteins required for virus replication, transcription, assembly and cell egress. In addition, these developments have paved the way for engineering these viruses for vaccine and gene therapy purposes. Moreover, using reverse genetics approaches it has been possible to develop cell-based minireplicon or minigenome (MG) assays to conduct studies under BSL2 conditions to dissect many aspects of the molecular and cell biology associated with the life cycle of BSL4 viruses. MG-based assays have also provided the foundations for the development of novel screening strategies to identify and validate compounds that could potentially be developed into effective antiviral drugs.

2. Impact of arenaviral infections in human health
==================================================

Arenaviruses cause chronic infections of rodents with a worldwide distribution ([@bib18]). Asymptomatically infected animals move freely in their natural habitat and may invade human dwellings. Humans are infected most likely through mucosal exposure to aerosols, or by direct contact between infectious materials and abraded skin. These infections are common and in some cases severe.

The family *Arenaviridae* consists of one unique genus (Arenavirus) with 22 recognized species that are classified into two distinct groups: Old World (OW) and New World (NW) ([@bib18]). This classification was originally established based on serological cross-reactivity, but it is well supported by recent sequence-based phylogenetic studies. Genetically, OW arenaviruses constitute a single lineage, while NW arenaviruses segregate into clades A, B, and C. The OW arenavirus Lassa virus (LASV) and several NW arenaviruses including Junin virus (JUNV), cause hemorrhagic fever (HF) in humans, which represents a serious public health problem in endemic areas ([@bib72], [@bib88], [@bib43], [@bib18], [@bib37], [@bib55]) ([Table 1](#tbl1){ref-type="table"} ).Table 1Geographic distribution and natural reservoirs of arenaviruses known to cause disease in humansArenavirusGeographic distributionNatural reservoirHuman diseaseLCMVEurope and AmericasMus domesticusLCMPossibly also other regionsMus musculusCongenital disorders  LASVWest AfricaMastomys speciesLassa fever (LF)JUNVArgentine pampasCalomys musculinusArgentine HF (AHF)MACVBolivia (Beni region)Calomys callosusBolivian HF (BHF)  GTOVVenezuelaSigmodon alstoniVenezuelan HF (VHF)Zygodontomys brevicauda  SABVBrazilUnknownUnassignedWWAVUSA (NM, CA)Neotoma albigulaUnassigned[^1]

LASV is estimated to infect several hundred thousand individuals yearly in its endemic regions of West Africa, with the highest incidence affecting the "Mano River Union (MRU) countries", resulting in a high number of Lassa fever (LF) cases associated with significant mortality and high morbidity ([@bib55]). In recent years, increased air travel between Africa and other areas has led to the importation of cases into the United States, Europe, Japan, and Canada ([@bib51], [@bib42], [@bib52]). JUNV, which is endemic to the humid pampas of Argentine, causes Argentine HF (AHF) that if left untreated has a high (15--30%) case-fatality rate ([@bib37]). Moreover, it is worth noting that compelling evidence indicates that the worldwide-distributed prototypic arenavirus LCMV is a neglected human pathogen of clinical significance, especially in cases of congenital infection leading to hydrocephalus, mental retardation and chorioretinitis in infants ([@bib54], [@bib4], [@bib5], [@bib76], [@bib6]). In addition, LCMV poses a special threat to immunocompromised individuals, as tragically illustrated by recent cases of transplant-associated infections by LCMV with a fatal outcome in the USA ([@bib38], [@bib89]).

The arenavirus potential for person-to-person transmission together with the likelihood that aerosolized forms of these viruses would be highly infectious to humans, have led to the inclusion of HF arenaviruses and LCMV within Category A biological agents that pose a significant biodefense concern ([@bib16]). These concerns are aggravated by the lack of licensed vaccines or effective treatment. Therefore, it is important to develop novel effective anti-arenavirus therapies and vaccines.

Evidence indicates that morbidity and mortality associated with LASV infection, and likely other HF arenavirus infections, are associated with, at least partly, the failure of the host\'s innate immune response to restrict virus replication and to facilitate the initiation of an effective adaptive immune response ([@bib72]). Accordingly, the extent of viremia is a highly predictive factor for the outcome of LF patients. This scenario would suggest that therapeutic interventions resulting in reduced virus load might suffice, despite the lack of complete virus clearance, to promote the recovery of appropriate host defense responses to control virus multiplication and associated disease.

Besides their significant in human health, arenaviruses are also important model systems to study virus--host interactions. Studies using the prototypic arenavirus LCMV have led to major advances in virology and immunology that apply universally to other microbial infections and viral infections of humans ([@bib80], [@bib144]). The outcome of LCMV infection of its natural host the mouse varies dramatically depending on the species, age, immune status and genetic background of the host, as well as the route of infection, and the strain and dose of infecting virus ([@bib80], [@bib144], [@bib18]). This provides investigators with a rather unique model system where to investigate parameters that critically affect the phenotypic heterogeneity often associated with infection by the same virus.

3. Current strategies to combat arenaviruses
============================================

3.1. Arenavirus vaccines
------------------------

Efforts to develop arenavirus vaccines have been focused on JUNV and LASV, the causative agents of AHF and LF. The live attenuated Candid 1 strain of JUNV was shown to induce a strong neutralizing antibody response in several animal models, as well as in humans, that correlated with protection against highly virulent strains of JUNV ([@bib36], [@bib37]). In a double blind study involving agricultural workers in the endemic area of Argentine Candid 1 strain proved to be an effective vaccine, without serious adverse effects ([@bib69]). However, the Candid 1 vaccine is licensed only as an investigational new drug in the U.S. and studies addressing the stability of its attenuation, long-term immunity and safety have not been conducted. Sequence comparison between the Candid 1 and virulent strains of JUNV have shown multiple mutations within NP, GP and L are associated with the vaccine strain, but their relative contributions to attenuation have not been determined.

LASV is the arenavirus with the highest impact on public health, due to its high incidence within the vast endemic area of West Africa where estimates of virus exposure, based on antibody prevalence, range from 4% to 6% in Guinea to 15% to 20% in Nigeria ([@bib55]). Therefore, the development of an effective and safe vaccine would represent a major accomplishment, not only in West Africa but also in other geographic regions due to the risk of imported cases of LF posed by increased international travel. Contrary to the situation found with JUNV and AHF, the neutralizing antibody response is not predictive of survival of LF ([@bib72]). Therefore, it is likely that the mechanisms responsible for the success of the JUNV Candid 1 strain vaccine for AHF may not serve the same purpose in the case of LF.

Different approaches have been pursued aiming at the development of a safe and effective vaccine against LASV, including DNA immunization protocols ([@bib103]), and the use of recombinant salmonella ([@bib31]). Recombinant vaccinia viruses expressing LASV NP or GP have been shown to provide both guinea pigs and non-human primates with protective cell-mediated immunity against lethal challenge ([@bib39]). However, the high prevalence of HIV in West Africa and the safety profile of vaccinia virus raise serious doubts about the potential implementation of this approach. Alphavirus-based vectors have been used to induce protective immunity in guinea pigs ([@bib96]), and more recently a recombinant vesicular stomatitis virus (VSV), in which the LASV GP replaced the VSV G, was shown to provide protection against lethal challenge ([@bib44]). In both of these studies the LASV challenge was done 28 days after immunization, so it remains to be determined whether these recombinant vaccines provide long-term protection -- a highly relevant issue, due to a cumulative lifetime risk of exposure to LF vaccine within the West Africa human population.

Another approach pursued in the development of a vaccine against LF is induction of heterologous immunity by using a closely related but less pathogenic virus. Thus, LCMV has been shown to be able to protect non-human primates against LF ([@bib56]). More recently, a reassortant virus between LASV and the genetically closely related NW arenavirus Mopeia (MOPV), called ML29, was found to protect guinea pigs against LASV induced disease ([@bib67]). However, safety profiles for LCMV and MOPV in humans have not been determined.

The development of reverse genetics systems for JUNV and LASV, similar to the one described for LCMV, would facilitate the elucidation of the genetic determinants of JUNV and LASV virulence. This, in turn, should help with the design of safer live attenuated vaccines by minimizing concerns related to possible reversion to virulence, establishment of persistent infection and in general conditions associated with high risk for replicating viruses including immunocompromised individuals. The power of reverse genetics as a tool for arenavirus vaccine development is illustrated by recent findings obtained with a recombinant LCMV expressing the surface GP of VSV serotype Indiana instead of its own GP (rLCMV/INDG) ([@bib92]). In mice, rLCMV/INDG exhibited a highly attenuated phenotype that remained stable upon long-term propagation in immunocompromised mice ([@bib8]), but it was able to elicit very strong, long-term T cell-mediated immunity against lethal challenge with wild-type LCMV ([@bib8]).

3.2. Antiviral drugs
--------------------

Current therapeutic measures against AHF are centered around the transfusion of immune plasma in defined doses of neutralizing antibodies during the prodromal phase of illness ([@bib37]), which is complicated by the difficulties of maintaining appropriate stocks of immune plasma, and the difficulty of detecting AHF in its early stages, when immune plasma therapy exerts its maximal efficacy.

In vitro and in vivo studies have documented the prophylactic and therapeutic value of the nucleoside analogue ribavirin (Rib) (1-b-[d]{.smallcaps}-ribofuranosyl-1,2,4-triazole-3-carboxamide) against several arenaviruses ([@bib2], [@bib28]). Moreover, Rib has been shown to reduce significantly both morbidity and mortality in humans associated with LASV ([@bib73], [@bib2], [@bib28]), and experimentally in Machupo ([@bib57]) and JUNV infections ([@bib74]), if given early in the course of clinical disease. The mechanisms by which Rib exerts its anti-arenaviral action remain poorly understood, but likely involve targeting different steps of the virus life cycle ([@bib82], [@bib64]). Recent evidence indicates that Rib can be used as substrate by the RdRp of some riboviruses leading to C to U and G to A transitions ([@bib27], [@bib19], [@bib82]). This mutagenic activity of Rib has been linked to its antiviral activity via lethal mutagenesis ([@bib19]). However, Rib inhibited very strongly LCMV replication without exerting any noticeable mutagenic effect on the virus genome RNA ([@bib105]). In humans, treatment causes a reversible anemia, and the drug has also caused birth defects in laboratory animals, so that it may not be prescribed to pregnant women. In addition, oral Rib is significantly less effective than the one administered intravenously, which poses logistic complications in regions with limited clinical infrastructure.

Several Rib-related inhibitors of IMP dehydrogenase, including ribamidine (1-beta-[d]{.smallcaps}-ribofuranosyl-1,2,4-tiazole-3-carboxamide) ([@bib2]), as well as acyclic and carbocyclic adenosine analogue inhibitors of *S*-adenosylhomocysteine (SAH) hydrolase ([@bib1]) have been show to have anti-arenavirus activity. Moreover, a variety of sulfated polysaccharides exhibited significant and specific anti-arenavirus activity ([@bib1]). Likewise, phenotiazine compounds ([@bib20]) and myristic acid analogues ([@bib23]), as well as brassinosteroids ([@bib133]), have been reported to have activity against several arenaviruses. In general these compounds displayed only modest and rather non-specific effects, often associated with significant toxicity.

Recently a high-throughput screening (HTS) based on a virus-induced cytopathic effect (CPE) assay successfully identified a potent small-molecule inhibitor of HF New World arenaviruses that acts by targeting the viral GP ([@bib15]). Likewise, cell-based HTS based on the use of pseudotyped virion particles bearing the GP of highly pathogenic arenaviruses identified several small-molecule inhibitors of virus cell entry mediated by LASV GP ([@bib60]). These findings illustrate how complex chemical libraries used in the context of appropriate screening assays can be harnessed into a powerful tool to identify candidate antiviral drugs with highly specific activities. To this goal, recent progress in the molecular and cell biology of arenaviruses, including the development of reverse genetics systems, have opened new avenues for the identification of steps in the arenavirus life cycle that are amenable to drug targeting and the development of appropriate screening strategies to identify such drugs.

4. Molecular and cell biology of arenaviruses
=============================================

Arenaviruses are enveloped viruses with a bi-segmented, negative-sense, single-stranded RNA genome and a life cycle restricted to the cell cytoplasm. Each genomic RNA segment, L (ca 7.3 kb) and S (ca 3.5 kb), uses an ambisense coding strategy to direct the synthesis of two polypeptides in opposite orientation, separated by a non-coding intergenic region (termed IGR) with a predicted folding of a stable hairpin structure ([@bib18]) ([Fig. 1](#fig1){ref-type="fig"} ). The S RNA encodes the viral nucleoprotein, NP (ca 63 kDa) and the virion surface glycoprotein precursor, GPC (ca 75 kDa). The L RNA encodes the viral RNA-dependent RNA polymerase (RdRp, or L polymerase) (ca 200 kDa), and a small RING finger protein Z (ca 11 kDa).Fig. 1LCMV genome organization.

Viral mRNAs have extra non-templated nucleotides (nt) and appear to have a cap structure at their 5′-ends, but the origin of both the cap and 5′-non-templated nt extensions remain to be determined. NP and L polypeptides are translated from mRNAs with antigenomic sense polarity, whereas GPC and Z ORFs are not translated directly from genomic RNA species, but rather from genome-sense mRNAs that are transcribed using as templates the S and L antigenome RNA species, respectively. Transcription termination of subgenomic non-polyadenylated viral mRNAs was mapped to multiple sites within the distal side of the intergenic region (IGR), suggesting that the IGR acts as a bona fide transcription termination for the viral polymerase, which has been confirmed by more recent studies using reverse genetics approaches ([@bib91], [@bib65]).

Post-translational cleavage of GPC generates the three components that form the GP complex (GPc): the stable signal peptide (SSP, 58aa), GP1 (Mr 40--46 kDa), and GP2 (Mr 35 kDa) ([@bib18]). The arenavirus SSP is unique in that it remains stably associated with the GP complex following cleavage by signal peptidase and plays crucial roles in the trafficking of GP through the secretory pathway ([@bib32], [@bib33], [@bib140]). Generation of GP1 and GP2 of the OW arenaviruses LCMV and LASV was found to be mediated by the SKI-1/S1P cellular protease ([@bib10], [@bib59], [@bib92]). This finding has been extended to the NW arenaviruses Guanarito, Machupo and Junin ([@bib104]). Notably, the protease recognition site present in Guanarito GPC deviates from the originally reported S1P consensus sequence ([@bib104]), indicating that S1P specificity is broader than previously thought.

The surface of the virus envelope is decorated by evenly spaced projections, or spikes, that consist of complexes of GP1 and GP2. GP1 is located at the top of the spike and is held in place by ionic interactions with the N-terminus of the transmembrane GP2, that forms the stalk of the spike ([@bib78], [@bib18]). GP1 is the virion attachment protein that mediates virus interaction with host cell surface receptors and subsequent virus cell entry via receptor mediated endocytosis ([@bib58]).

Once the viral ribonucleoprotein has been delivered into the cytoplasm of the infected cell, the associated polymerase directs the biosynthetic processes involved in RNA replication and gene transcription ([Fig. 2](#fig2){ref-type="fig"} ). Primary transcription initiated at the genome promoter located at the genome 3′-end results in synthesis of NP and L mRNA from the S and L segments, respectively. Subsequently the virus polymerase can adopt a replicase mode and moves across of the IGR to generate a copy of the full-length antigenome RNA (agRNA). This agRNA will serve as template for the synthesis of the GP (agS) and Z (agL) mRNAs. The agRNA species serve also as templates for the amplification of the corresponding genome RNA species. Assembly and cell release of infectious progeny involves the association of the viral ribonucleoprotein core with the surface GP complex, a process that requires the participation of Z ([@bib21]). Correct processing of GPC is required for the production of infectious virions ([@bib10], [@bib59], [@bib92]), which bud from the plasma membrane.Fig. 2Basic aspects of arenavirus RNA replication and gene transcription illustrated for the S segment. The L polymerase associated with the virus RNP initiates transcription from the genome promoter located at the genome 3′-end. Primary transcription results in synthesis of NP mRNA (or L mRNA in the case of the L segment). Subsequently the virus polymerase can adopt a replicase mode and moves across of the IGR to generate a copy of the full-length antigenome (ag) S RNA (or ag L RNA). This ag S RNA will serve as template for the synthesis of the GP mRNA (the ag L RNA will serve as template for the synthesis of the Z mRNA). The agRNA species serve also as templates for the amplification of the corresponding genome RNA species.

5. Arenavirus genetics
======================

5.1. Reassortment
-----------------

The segmented nature of the arenavirus genome permits the generation of reassortants between two parental viruses. For this, cells coinfected with both viruses serve as a mixing vessel to facilitate the generation of infectious progeny carrying all possible combinations of L/S genomes. Genetic or biochemical characterization of clonal populations derived from the infectious progeny makes it possible to identify the origins of the RNA segments, and thereby map specific phenotypes of the parental viruses to either the L or S segment. For example, the ability of LCMV to cause growth hormone deficiency in C3H mice ([@bib100]), or immunosuppression and persistence in adult immunocompetent mice ([@bib70], [@bib107]) have been mapped to the S segment. Similarly, the lethality of the WE strain of LCMV in guinea pigs ([@bib101]), and differences in virulence between LASV strains ([@bib67]) have been mapped to the L segment.

5.2. Reverse genetics
---------------------

Despite tremendous success in mapping a variety of arenavirus phenotypes to either the L or S segment, the use of reassortant viruses does not make it possible to assess the individual contribution of each of the potential multiple mutations that often are found between the L and S segments of two parental viruses. Likewise, the reassortment approach cannot be used to generate viruses with predetermined mutations in their genomes. This inability to genetically manipulate the arenavirus genome has hampered studies aimed at understanding its molecular and cell biology, as well as the role played by each viral gene product in virus--host interactions during both acute and persistent infections and associated diseases. Reverse genetics systems that support RNA replication and expression of arenavirus minigenomes have been developed for LCMV, as well as for LASV ([@bib47]) and the NW arenavirus Tacaribe (TCV) ([@bib66]), and have provided investigators with a novel and powerful approach for the investigation of the *trans*-acting factors and *cis*-acting sequences that control arenavirus replication and gene expression, as well as assembly and budding ([Fig. 3](#fig3){ref-type="fig"} ). The LCMV MG system is based on intracellular synthesis, via either plasmid-supplied T7 RNA polymerase or RNA polymerase I (pol-I), of RNA analogues (MG) that contains the 5′- and 3′-UTR and IGR *cis*-acting sequences required for the control of RNA synthesis mediated by the LCMV polymerase, and the ORF of a reporter gene in lieu of the NP ORF. Encapsidation of the pol-I or T7-derived LCMV MG RNA by plasmid-supplied NP generates a template that is recognized by the intracellularly reconstituted LCMV polymerase to direct synthesis of full-length anti-minigenome (aMG) RNA (replicate) and a subgenomic mRNA (transcript) that codes for the reporter gene of choice ([@bib61]). Incorporation into the transfection mix of GPC and Z-expressing plasmids allows for assembly and budding of infectious VLPs ([@bib62], [@bib85]).Fig. 3Schema of the LCMV MG rescue system. LCMV RNA analogues, or MG, with correct termini are synthesized intracellularly using either a T7 RP, or RNA pol-I, expression system. Cotransfection with plasmids expressing the viral *trans*-acting factors L and NP allow for the generation of viral RNP (MG RNA encapsidated by NP) that is substrate for the plasmid-supplied virus L polymerase. The virus polymerase directs the synthesis of two RNA species, the aMG RNA (replicative species) and a subgenomic mRNA that directs expression of the reporter gene of choice, CAT in this case. Incorporation of plasmids expressing Z and GP results in assembly and budding of infectious LCMV virus like particles (VLP).

Results from the LCMV MG system identified NP and L as the minimal viral *trans*-acting factors required for efficient RNA synthesis, both transcription and replication, mediated by the virus polymerase ([@bib61]). Similar findings have been now documented for LASV ([@bib47]) and TCV ([@bib66]). Notably, both genetic and biochemical evidence indicated that oligomerization of L is required for polymerase function ([@bib110]). The activity of the LCMV genomic promoter recognized by the virus polymerase requires both sequence specificity within the highly conserved 3′-terminal 19 nt of arenavirus genomes, and the integrity of the predicted panhandle structure formed via sequence complementarity between the 5′-and 3′-termini of viral genome RNAs ([@bib86]). Detailed structure-function studies using the LASV MG system ([@bib48]) revealed that the LASV promoter, and likely that of all arenaviruses, regulates transcription and replication in a coordinated manner. It is composed of two functional elements: a sequence-specific region from residue 1--12 and a variable complementary region from residue 13--19. The first region appears to interact with the replication complex mainly via base-specific interactions, while in the second region, base pairing between 3′- and 5′-termini of the promoter determines its activity.

The use of the LCMV MG rescue system also provided direct experimental evidence that the IGR is a bona fide transcription termination signal ([@bib91]). This finding has also been documented for TCV. Contrary to a widely accepted model for the control of arenavirus RNA replication and gene transcription, intracellular levels of NP do not play a key role in the control of the balance between RNA replication and transcription by the arenavirus polymerase ([@bib90]). The mechanisms determining whether the arenavirus polymerase complex behaves in a replicase or transcriptase mode remain to be elucidated.

Z was not required for intracellular transcription and replication of a LCMV MG, but rather Z exhibited a dose-dependent inhibitory effect on both transcription and replication of LCMV MG ([@bib61], [@bib24], [@bib25], [@bib26]). This inhibitory effect of Z has been also reported for TAV ([@bib66]) and LASV ([@bib47]). Z has been postulated to participate in virion morphogenesis ([@bib109], [@bib108]). For most enveloped viruses, a matrix (M) protein is involved in organizing the virion components prior to assembly, but arenaviruses do not have an obvious counterpart of M. However, we ([@bib85]) and others ([@bib120], [@bib130]) have shown that Z is the main driving force of arenavirus budding and that this process is mediated by the Z proline-rich late domain motifs (LDM) PTAP and PPPY, similar to those known to control budding of several other viruses including HIV and Ebola, via interaction with specific host cell proteins ([@bib41]). Consistent with this observation, Z exhibits features characteristic of bona fide budding proteins: the ability to bud from cells by itself and to efficiently substitute for other LDM ([@bib85]). Targeting of Z to the plasma membrane, the location of arenavirus budding, strictly required its myristoylation ([@bib87]). These data support a role of Z as the arenavirus counterpart of the M proteins found in many other NS RNA viruses, a notion that is consistent with recent ultrastructural data on arenavirus virions determined by cryo-electron microscopy ([@bib78]).

Infectious LCMV has been rescued entirely from cloned cDNAs using approaches based on both the T7 RNA polymerase ([@bib111]) and RNA pol-I ([@bib40]) to launch the intracellular synthesis of S and L antigenome RNA species, which are subsequently replicated and transcribed by the virus polymerase, which is intracellularly reconstituted via plasmid-supplied viral L and NP ([Fig. 4](#fig4){ref-type="fig"} ). The ability to generate rLCMV with predetermined specific mutations and analyze their phenotypic expression in its natural host, the mouse, would allow us to tackle a number of long-standing questions of the virus molecular biology, its relationship with the host cell and the specific role of the four known viral genes in arenavirus pathogenesis.Fig. 4Rescue of infectious rLCMV entirely from cloned cDNAs. Cells are transfected with plasmids that directed T7RP-or pol-I mediated intracellular synthesis of L and S antigenomic (Lag and Sag) RNA species, together with pol-II expression plasmids for the viral *trans*-acting factors L and NP (and also T7RP if required). At different times after transfection, cell culture supernatants are tested for production of infectious rlCMV. Production of rLCMV is readily and consistently detected at 48 h after transfection, which is followed by a rapid increase in virus production reaching titers of 10^7^ PFU/ml between 60 and 72 h post-transfection. Notably, we observed similar rescue efficiencies using either genomic or antigenomic polarities of the L and S RNAs. This finding indicates that annealing between viral mRNAs and genome, or antigenome, RNA species do not pose a significant problem for the rescue of LCMV, and likely arenaviruses in general. Likewise, both the T7RP and pol-I based rescue systems exhibited similar efficiencies.

6. Arenavirus MG systems as platforms for screening anti-arenaviral drugs
=========================================================================

MG rescue systems similar to those already established for LCMV, LASV and TCV could now be developed for other arenaviruses of interest. These MG systems provide investigators with excellent platforms to identify inhibitors of arenavirus replication and propagation and to dissect their mechanisms of action. Thus, the anti-arenavirus activity of Rib has been recreated in the LCMV ([@bib105]) and LASV ([@bib47]) MG rescue systems. In contrast, the myristoylation inhibitor 2-hydroxymyristic acid (2-OHM) that was shown to inhibit Z-mediated arenavirus budding ([@bib87]) did not affect, as predicted, MG RNA replication and expression, which further supports the feasibility of using cell-based MG rescue systems to identify drugs that interfere with specific steps of the arenavirus life cycle, and subsequently delineate the underlying mechanisms of action. Likewise, the use of an LCMV MG system was instrumental in assessing the specificity, efficacy and effects of siRNAs targeting different viral mRNAs ([@bib112]). The following sections discuss some examples of the use of MG systems to uncover novel anti-arenaviral strategies.

6.1. Targeting the arenavirus promoter
--------------------------------------

The sequence and structural constraints of the arenavirus genome promoter ([@bib86]) identified a new potential target for drugs capable of disrupting the interaction between the promoter and the virus polymerase complex, which is expected to have a strong deleterious impact on virus viability by affecting the essential biosynthetic processes of viral transcription and replication. The potential of RNA as a prime target for therapeutic intervention is gaining great interest ([@bib49], [@bib50], [@bib122], [@bib124], [@bib136], [@bib123]). The function of many RNA molecules depends on defined three-dimensional structure. The large variety of structures associated with RNA folding create unique binding pockets that provide potential targets for small molecules. Small molecules may interfere with RNA functions by a number of mechanisms including inhibition of the formation of competent RNA--protein complexes.

The study of small-molecule RNA effectors has primarily focused on the aminoglycosides ([@bib49], [@bib50], [@bib136], [@bib123]). The antibiotic activity associated with aminoglycoside targeting of bacterial 16S ribosomal RNA is a well-known success case. Despite their benefits, the efficacy of naturally occurring aminoglycosides has been limited due to the emergence of resistant microbes, oral inactivity, toxicity, and weak binding common to carbohydrates. During recent years there has been great progress in developing aminoglycoside-based analogues (mimetics) to circumvent these issues ([@bib115], [@bib116], [@bib139]). These advances have permitted the generation of complex combinatorial libraries of aminoglycosides that can be subjected to robust novel screening procedures ([@bib49], [@bib50], [@bib122], [@bib124], [@bib136], [@bib116], [@bib123], [@bib139]). These developments are facilitating the identification of drugs that bind specifically to a variety of RNA folds, thus opening new ways to expand the existing repertoire of protein-targeted therapeutics. The potential of aminoglycosides as antiviral molecules by acting on RNA has been illustrated by their ability to disrupt selectively the HIV-1 Rev-RRE ([@bib141]) and Tat-TAR ([@bib134]) interactions. Similar approaches could be used to select aminoglycosides that interact with the arenavirus promoter and disrupt its activity. The sequence conservation of the arenavirus promoter predicts that aminoglycoside-based small molecules selected based on their activity against the promoter of the prototypic arenavirus LCMV would be also active against LASV and other HF arenaviruses.

The high sequence and structural conservation of the core of the arenavirus genome promoter raises also the possibility of using a method for in vitro selection of combinatorial oligonucleotide libraries referred to as SELEX ("Systematic Evolution of Ligands by Exponential enrichment") ([@bib35], [@bib102], [@bib129]) to select nucleic acid-based molecules (aka aptamers) for target proteins. Aptamers usually exhibit tight binding to their protein targets, high specificity and minimal to no immunogenicity. They are therefore considered to be novel promising therapeutic drugs. SELEX could be used to select for aptamer molecules to target the arenavirus L polymerase and disrupt either the L-virus promoter or L--L interactions, both of which are strictly required for initiation of RNA synthesis.

6.2. Targeting the IGR
----------------------

Early studies documented that the 3′ ends of the non-polyadenylated LCMV mRNAs were heterogeneous and mapped within the IGR ([@bib77]). All arenavirus IGR sequences are predicted to fold into single or double stem-loop structures ([@bib77], [@bib18]), suggesting a structure-dependent transcription termination mechanism reminiscent of rho-independent termination in prokaryotes ([@bib137], [@bib128]). This prediction has received direct experimental support from results obtained using arenavirus MG systems ([@bib91], [@bib65]). Unexpectedly, LCMV MGs without IGR were dramatically impaired in their ability to passage reporter gene activity via infectious VLP ([@bib91]), suggesting that in addition to its role in the control of RNA synthesis, the IGR plays a role in virus assembly or budding, or both, required for the efficient propagation of LCMV infectivity. In this regard, it is worth noting that LCMV genome and antigenome RNA species present in arenavirus RNPs were found to be sensitive to cleavage by very low concentrations of Rnases, suggesting that the arenavirus genome and antigenome are not tightly encapsidated, and are thereby potentially vulnerable to targeting. There is significant sequence heterogeneity between the IGR of the L and S segments of the each arenavirus species and between the L and S segments of different species. However, as with the virus genome promoter, IGRs are predicted to have a conserved folding that could provide a suitable target.

6.3. Targeting the L--L interaction required for arenavirus polymerase activity
-------------------------------------------------------------------------------

The arenavirus L protein has the characteristic sequence motifs that are conserved among the RdRp (L proteins) of NS RNA viruses. Sequence alignment shows six conserved domains ([@bib93], [@bib127]). The proposed polymerase module of L is located within domain III, which contains highly conserved amino acids within motifs designated A and C. The SDD sequence characteristic of motif C of segmented NS RNA viruses, and the presence of the highly conserved D residue within motif A, are strictly required for the function of the LCMV L polymerase ([@bib110]). These studies also showed that many of the mutant L proteins exhibited a strong dominant-negative (DN) effect under assay conditions in which the wild-type and mutant L proteins did not compete for template RNA or other viral or cellular *trans*-acting proteins required for polymerase activity ([@bib110]). These results were highly suggestive of L--L interaction being required for LCMV polymerase activity.

Consistent with these genetic data, results from co-immunoprecipitation studies using L proteins containing two different tags, HA and Flag, provided biochemical evidence for L--L interaction ([@bib110]). Intragenic complementation has been documented for the L genes of several NS RNA viruses ([@bib99], [@bib118]). Consistent with this, direct L--L physical interaction has been demonstrated for the paramyxoviruses Sendai ([@bib118]) and parainfluneza virus 3 (PIV3) ([@bib119]), and this L oligomerization was required for polymerase activity. These results suggest that disruption of this L--L interaction would have a potent inhibitory effect on polymerase activity.

Cell-based MG rescue assays are particularly appealing for identifying small molecules capable of disrupting L--L interaction, thus resulting in inhibition of arenavirus polymerase activity. Protein--protein interactions have been generally regarded as difficult or refractory drug targets for small molecules, because of the widely shared assumption that they are unlikely to disturb large protein interfaces. However, recent evidence suggests that the affinity between interacting proteins may be governed only by a minor part of the interface region ([@bib135]). Targeting these highly "localized" surfaces may be sufficient for inhibiting protein--protein interactions. Notably, combinatorial libraries of small molecules generated via solution-phase methodology have been uniquely successful in the identification of small molecules that inhibit protein--protein interactions for a series of significant biological targets ([@bib14], [@bib13], [@bib12]). Similar approaches should be applicable to screens to identify small-molecule inhibitors of arenavirus polymerases.

6.4. Targeting the S1P-mediated proteolytic processing of arenavirus GPC
------------------------------------------------------------------------

S1P protease is encoded by the membrane bound transcription-factor protease site 1 gene and is an endoplasmic reticulum (ER)/early Golgi membrane-anchored serine protease ([@bib106], [@bib117]). S1P cleaves within the motif R-X-(hydrophobic)-XI. Despite its broad consensus sequence, S1P exhibits exquisite substrate specificity and is involved in proteolytic processing of a defined set of cellular proteins including brain derived neurotrophic factor (BDNF) precursor protein ([@bib117]) and the sterol regulatory element-binding proteins (SREBP-1 and SREBP-2), which are membrane-associated transcription factors that regulate genes involved in lipid metabolism and cholesterol synthesis ([@bib17], [@bib46], [@bib97], [@bib98]). S1P contributes also to the regulation of ATF6 and other transcription factors controlling the unfolded protein response (UPR) of the cell to bring the folding capacity of the ER in line with the folding demand ([@bib138], [@bib114], [@bib142], [@bib143]).

S1P-mediated processing of the GPs of OW arenaviruses LCMV and LASV has been shown to be crucial for the production of infectious progeny and for cell-to-cell propagation ([@bib63], [@bib10], [@bib59], [@bib92]). Notably, studies on LCMV and JUNV infection in cells deficient in S1P have indicated that the emergence of variants capable of growing independent of S1P-mediated processing of GPC appears to be highly unlikely (Kunz and de la Torre, unpublished). These findings strongly support the view that inhibitors of S1P protease represent promising drug candidates. It is worth noting that S1P also mediates processing of the major GP precursor of Crimean-Congo hemorrhagic fever virus (CCHFV), a member of the Nairovirus genus with the family *Bunyaviridae* ([@bib113], [@bib132]). Therefore, compounds exerting anti-arenaviral activity by inhibiting the processing of the virus GPC precursor would be likely to be effective also against CCHFV, a tick-borne pathogen that causes HF in humans throughout regions of Africa, Asia and Europe.

The key role of S1P in the regulation of lipid metabolism and cholesterol biosynthesis has raised considerable interest in developing specific inhibitors of S1P activity. The non-peptide general serine protease inhibitor aminoethyl benzenesulfonyl fluoride (AEBSF) was reported to inhibit S1P ([@bib7]), but other studies questioned this finding ([@bib34], [@bib11]). S1P was not blocked by specific inhibitors of other proprotein convertases, but 3,4-dichloroisocoumarin (DCI) at low nanomolar concentrations efficiently inhibited S1P ([@bib11]). Likewise, mutants of the preprosegment of S1P and variants of the serpin α1-antitrypsin that were designed to react with S1P by insertion of reactive loop sequences have been also evaluated as candidate protein-based inhibitors ([@bib95]). These studies identified several molecules that significantly blocked S1P-mediated processing of SREBP-1 and ATF6 and the GP of CCHF virus when expressed in cells providing proof-of-principle.

More recent efforts that have focused on the development of peptide-based irreversible S1P inhibitors have identified decanoylated chloromethylketone (CMK)-derivatized peptides containing the RRLL recognition sequence as potent suicide inhibitors of S1P ([@bib83]). These inhibitors also blocked the activity of the furin in vitro, but showed specificity towards S1P when used in cells at \<100 μM. Because they cause irreversible inhibition of the catalytic activity of S1P against all targets, whether host cell or pathogen-derived, their use would pose difficulties for a therapeutic approach that aims at specific inhibition of S1P-mediated processing of viral GPs without affecting S1P\'s activity towards its cellular substrates. Consequently, strategies aimed at targeting S1P-mediated processing of the arenavirus GPC should pursue the identification of compounds that specifically block processing of arenavirus GPCs.

Many viruses, including Japanese encephalitis ([@bib121]), murine retroviruses ([@bib29], [@bib30]), hepatitis C ([@bib84]), paramyxoviruses ([@bib125]), human cytomegalovirus ([@bib53]), SARS corona virus ([@bib131]), and West Nile virus ([@bib75]) induce the UPR. Expression of the viral envelope GP in the ER is often a major trigger for the UPR, due to an overwhelming of the folding capacities of the ER resulting in the accumulation of unfolded viral GP. Some aspects of the UPR, such as an increase in the ER\'s folding capacity and metabolic adaptations, are likely favorable for viral infection, while others, such as the suppression of protein translation and increased ER protein degradation, appear to be disadvantageous. Non-cytolyic viruses, such as arenaviruses, that readily persist may have evolved mechanisms to differentially modulate the different branches of the UPR to favor viral replication and gene expression maintaining aspects of the UPR that are beneficial for the host cell. Arenaviruses may have evolved to use S1P instead of other proteases of the proprotein convertase family commonly used for processing of viral GPs, e.g. furin, because the interaction of GP with S1P allows the virus to manipulate the host cell\'s UPR. This feature could pose additional barriers to the emergence of viral variants capable of using an alternative protease for the processing of GPC, which would enhance the antiviral power of inhibitors of S1P.

6.5. Targeting arenavirus budding
---------------------------------

As with other bona fide viral budding proteins, Z-mediated budding of arenaviruses requires the interaction of Z with specific cellular factors within the endosomal/MVB pathway ([@bib94]). The identification and characterization of LFV Z-host protein interactions involved in virus budding may uncover novel antiviral targets and facilitate the development of screening strategies to identify drugs capable of disrupting budding and preventing virus propagation. In this regard, we have already identified TSG101 and CHMP3, members respectively of the ESCRT-I and ESCRT-III complexes, as Z-interacting cellular proteins required for budding. Notably, down-regulation of TSG101 via siRNA ([@bib85]) or the use of dominant-negative forms of CHMP3 (Perez and de la Torre, unpublished) resulted in dramatically reduced levels of Z-mediated budding.

The ability of Z to direct self-budding in the absence of other viral proteins should facilitate the development of assays amenable to both genetics and chemical HTS to identify host cellular proteins required for Z-mediated budding, as well as small-molecule inhibitors of this process. To this end, the emergence of RNA interference as a pathway that allows the modulation of gene expression has enabled functional genetic screens in mammalian cell types ([@bib3], [@bib9], [@bib81]). Likewise, combinatorial chemical libraries have emerged as a leading source of compounds, which can be screened to identify small-molecule inhibitors of Z-mediated budding, using cell-based assays.

Methods currently used to assess budding mediated by wild-type or mutant viral proteins rely mainly on the recovery by high-speed ultracentrifugation or immunoprecipitation of VLPs present in culture supernatants of cells previously transfected with a plasmid expressing the protein of interest. The presence of the corresponding protein in the recovered VLPs is detected based on the use of radiolabeled proteins or by Western blot using appropriate antibodies. These methods are not easily amenable to HTS to identify inhibitors of Z-mediated arenavirus budding. An ideal HTS assay would permit assessment of Z budding by examining tissue culture supernatants directly, such as with an enzymatic assay that could identify cellular mediators of Z budding.

Recent work with Ebola virus VP40 described a luciferase-based budding assay that might be suitable for the development of HTS ([@bib71]). This assay, however, had some significant limitations: it measured the incorporation of firefly luciferase (FFL) into VP40 VLPs, and thereby did not directly measure the budding capability of VP40, and it required ultracentrifugation of the VLPs for detection of budding. These results, however, raised the possibility of using chimeric proteins consisting of the bona fide viral budding protein fused to an appropriate reporter gene such as FFL as tools to develop assays in which budding could be rapidly and quantitatively assessed by measuring levels of gene reporter activity. In this regard, recent findings have shown that the fusion of the smaller (185 amino acids) luciferase from *Gaussia princeps* (GLuc) ([@bib126]) to Z resulted in a chimeric protein (Z-GLuc) that retain wild-type Z budding activity that could be monitored by direct measuring of GLuc activity in TCS of Z-GLuc transfected cells (A.A. Capul and J.C. de la Torre, manuscript submitted). Initial studies have shown that this Z-GLuc based budding assay consistently exhibits a high (average 10-fold) signal-to-noise ratio, as described ([@bib45]), suggesting that it should be amenable for the development of HTS to identify small-molecule inhibitors of Z-mediated budding.

7. Generation of recombinant arenaviruses for the development of HTS to identify novel anti-arenaviral drugs
============================================================================================================

The development of HTS to simultaneously screen a broad class of compounds against the functions of multiple viral targets required for the completion of the arenavirus life cycle would be of great value for the identification of novel anti-arenaviral drugs. To this aim the use of rLCMV expressing appropriate reporter genes should facilitate the development of assays amenable to HTS formats.

A variety of recombinant LCM viruses (rLCMV) have been rescued entirely from cloned cDNAs ([@bib92], [@bib40], [@bib111]). In contrast, the rescue of rLCMV expressing additional heterologous gene products posed unexpected difficulties. Several strategies successfully employed with other NS RNA viruses to express additional gene products did not work in the case of LCMV (S. Emonet and J.C. de la Torre, unpublished). These included: (1) incorporation into the virus genome of an additional transcription unit containing the ORF of interest; (2) use of a viral or cellular internal ribosome entry site (IRES) to direct cap-independent synthesis of a protein coded by an ORF located downstream within a polycistronic mRNA; and (3) use of the self-cleaving 2A protease of picornaviruses for efficient processing of an initially synthesized polypeptide to generate independently the proteins coded by the ORFs located up- and downstream of the 2 A. Recent findings, however, have supported the feasibility of rescuing a rLCMV containing three genome segments: 1 L and 2 S (S. Emonet and J.C. de la Torre, unpublished). This has opened the possibility of rescuing a three-segment rLCMV, in which each of the two S segments contains a gene of interest (GOI) instead of one of either GPC or NP. The rationale behind this approach is that the physical separation of GP and NP into two different S segments would represent a strong selective pressure to select and maintain a virus capable of packaging 1 L and 2 S segments ([Fig. 5](#fig5){ref-type="fig"} ). This strategy has been used to generate a variety of tri-segmented (2 S + 1 L) rLCMV, where in each of the S segments one of the two virus genes (GPC or NP) was replaced by a gene of interest, including reporter genes such as CAT or luciferase. Notably, the genotype, growth properties and reporter gene expression of these rLCMV were stably maintained during serial passage. This new development provides investigators with a fantastic tool for the development of HTS assays to globally identify inhibitors of arenavirus multiplication.Fig. 5Use of a tri-segments genome strategy to incorporate additional genes within the arenavirus genome. Each of the two S segments was altered to replace one of the viral ORF by the ORF of a gene of interest (GOI). The physical separation of GP and NP into two different S segments would represent a strong selective pressure to select and maintain a virus capable of packaging 1 L and 2 S segments.

8. Perspectives
===============

The findings described in the previous sections have illustrated the potential of using arenavirus MG rescue systems as platforms for drug screening. MG cell-based assays offer a number of benefits in the discovery and analysis of antiviral compounds. They permit the effect of an antiviral compound to be observed in the context of living cells, so that any compounds that show antiviral activity necessarily are able to enter and act within living cells. They also allow the immediate identification of compounds with undesirable cytotoxicity, using well-established assays. Because viral functions related to infectivity are not required for MG RNA replication and expression, these systems are safer and easier to work with than infectious pathogenic arenaviruses. It is worth noting that the implementation of siRNA-based screens in the context of cell-based MG rescue assays can identify host cell proteins that play key roles in arenavirus RNA replication and gene expression and thereby open potential novel targets that could be used in the development of effective anti-arenaviral drugs. The ability to generate rLCMV with predetermined genetic modifications would also facilitate studies aimed at identifying mechanisms of antiviral drug action and the possible generation and selection of drug-resistant viral variants.

The development of reverse genetics systems for several arenaviruses has also opened new research avenues to study the biology of this virus family, which contains several members highly relevant to human health. In addition, the prototypic arenavirus LCMV remains a very robust model system to study virus--host interactions in the context of infection of the natural host, the mouse. The ability to manipulate the LCMV genome and generate rLCMV with predetermined mutations allows investigators to gain a detailed understanding of the roles played by different viral genes in specific phenotypic outcomes, ranging from acute fatal meningitis to immunosuppression and chronic infections associated with neurobehavioral abnormalities.
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[^1]: *Acronyms*: LCMV, lymphocytic choriomeningitis virus; LASV, Lassa virus; JUNV, Junin virus; MACV, Machupo virus; GTOV, Guanarito virus; SABV, Sabia virus; WWAV, white water arroyo virus; LF, Lassa fever; HF, hemorrhagic fever; AHF, Argentine HF; BFH, Bolivian HF; VHF, Venezuelan HF.
